Abstract
We did not observe elevated ghrelin levels in adult GHD subjects and GH replacement therapy did not modify circulating ghrelin levels, despite significant decreases in body fat mass and percentage body fat. It is conceivable that the lack of ghrelin modifications after long-term GH therapy was due to the reduction of adiposity and insulin on one hand, and increased GH secretion on the other. However, it is still possible that systemic ghrelin is involved in the development of obesity, both in normal and GHD subjects.
| Original language | English |
|---|---|
| Pages (from-to) | 711-716 |
| Number of pages | 6 |
| Journal | European Journal of Endocrinology |
| Volume | 145 |
| DOIs | |
| Publication status | Published - Dec 2001 |
Bibliographical note
© 2001 Society of the European Journal of EndocrinologyUN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Research programs
- EMC 02-01-38-01-01
Fingerprint
Dive into the research topics of 'Systemic ghrelin levels in subjects with growth hormone deficiency are not modified by one year of growth hormone replacement therapy'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver